At present, there is sufficient evidence supporting that patients may experience better therapeutic outcome when there is a complete pathological response to neoadjuvant chemotherapy.6 Importantly, as recommended by Gianni et al.7, for female patients with HER2-positive breast cancer, neoadjuvant chemotherapy associated with trastuzumab as adjuvant therapy should be considered to improve the event-free survival rate, survival rate as well as clinical and pathological tumor response. The gene discussed is ERBB2; the disease is breast carcinoma.